Buprenorphine prescription and the increased relative cost [4]

Addiction

Volumn 100, Issue 9, 2005, Pages 1373-1374

  Alvarez, F Javier ^a   González Saiz, Francisco ^b  

^a UNIVERSITY OF VALLADOLID   (Spain)

^b Andalusian Foundation for Drug Abuse Attendance   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; METHADONE;

COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; LETTER; OPIATE ADDICTION; PRESCRIPTION;

BUPRENORPHINE; COST-BENEFIT ANALYSIS; DRUG COSTS; ENGLAND; HUMANS; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; PRESCRIPTIONS, DRUG;

EID: 24344498643     PISSN: 09652140     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2005.01211.x     Document Type: Letter

References (12)

1. De Wet, C. J., Reed, L. J. & Beran, J. (2005) The rise of buprenorphine prescribing in England: analysis of NHS regional data. 2001-03. Addiction, 100, 495-499.
2. Conférence de Consensus. (2004) Stratégies thérapeutiques pour les personnes dépendantes des opiacés: place des traitements de substitution. Texte des recommmandations. Alcoologie et Addictologie, 26, 6S-12S.
3. Sullivan, L. E., Metzger, D. S., Fudala, P. J. & Fiellin, D. A. (2005) Decreasing international HIV transmission: the role of expanding access to opioid agonist therapies for injection drug users. Addiction, 100, 150-158.
4. Fiellin, D. A., Cléber, H., Trumble-Heiduck, J. G., McLellan, A. T. & Kosten, T. R. (2004) Consensus statement on office-based treatment of opioid dependence using buprenorphine. Journal of Substance Abuse Treatment, 27, 153-159.
5. Álvarez, F. J., González-Sain, F., Meana, J. J., Pineda, J. & Roncero, C. (2005) SET position paper: buprenorphine in the treatment of opioid dependence in Spain. Trastornos Adictivos, 7, 44-46.
6. Rosenheck, R. & Kosten, T. R. (2001) Buprenorphine for opiate addiction: potential economic impact. Drug and Alcohol Dependence, 63, 253-262.
7. Barnett, P. G., Zaric, G. & Brandeau, M. L. (2001) The cost-effectiveness of buprenorphine maintenance therapy for the opiate addiction in the United States. Addiction, 96, 1267-1278.
8. Gibson, A. E., Doran, C. M., Bell, J. R., Ryan, A. & Lintzeris, N. (2003) A comparison of buprenorphine treatment in clinic and primary care setting: a randomised trial. Medical Journal of Australia, 179, 38-42.
9. Doran, C. M., Shanahan, M., Bell, J. & Gibson, A. (2004) A cost-effectiveness analysis of buprenorphine-assisted heroin withdrawal. Drug and Alcohol Review, 23, 171-175.
10. Doran, C. M., Shanahan, M., Mattick, R. P., Ali, R., White, J. & Bell, J. (2003) Buprenorphine versus methadone maintenance: a cost-effectiveness analysis. Drug and Alcohol Dependence, 71, 295-302.
11. Lintzeris, N., Ritter, A., Panjari, M., Clark, N., Kutin, J. & Bammer, G. (2004) Implementing buprenorphine in community setting in Australia: experiences from the buprenorphine implementation trial. American Journal on Addictions, 13, S29-S41.
12. Harris, A. H., Gospodarevskaya, E. & Ritter, A. J. (2005) A randomised trial of the cost effectiveness of buprenorphine as an alternative to methadone maintenance treatment for heroin dependence in a primary care setting. Pharmacoeconomics, 23, 77-91.